These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1166 related articles for article (PubMed ID: 27622751)

  • 21. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
    von Minckwitz G; Procter M; de Azambuja E; Zardavas D; Benyunes M; Viale G; Suter T; Arahmani A; Rouchet N; Clark E; Knott A; Lang I; Levy C; Yardley DA; Bines J; Gelber RD; Piccart M; Baselga J;
    N Engl J Med; 2017 Jul; 377(2):122-131. PubMed ID: 28581356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
    Peterson DJ; Truong PT; Sadek BT; Alexander CS; Wiksyk B; Shenouda M; Raad RA; Taghian AG
    Ann Surg Oncol; 2014 Oct; 21(11):3490-6. PubMed ID: 24841346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
    Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
    Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of trastuzumab on locoregional recurrence in human epidermal growth factor receptor 2-overexpressing breast cancer patients treated with chemotherapy and radiotherapy.
    Jeon SH; Shin KH; Kim JH; Kim K; Kim IA; Lee KH; Kim TY; Im SA
    Breast Cancer Res Treat; 2018 Dec; 172(3):619-626. PubMed ID: 30209731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.
    Seferina SC; de Boer M; Derksen MW; van den Berkmortel F; van Kampen RJ; van de Wouw AJ; Joore M; Peer PG; Voogd AC; Tjan-Heijnen VC
    Oncologist; 2016 May; 21(5):555-62. PubMed ID: 27009939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trial.
    Papakonstantinou A; Matikas A; Bengtsson NO; Malmström P; Hedayati E; Steger G; Untch M; Hübbert L; Johansson H; Hellström M; Gnant M; Loibl S; Greil R; Moebus V; Foukakis T; Bergh J
    Cancer; 2020 Mar; 126(6):1175-1182. PubMed ID: 31851385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients.
    Watanuki R; Hayashida T; Kawai Y; Kikuchi M; Nakashoji A; Yokoe T; Toyota T; Seki T; Takahashi M; Kitagawa Y
    Int J Clin Oncol; 2019 Jul; 24(7):807-814. PubMed ID: 30810890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer.
    Norton N; Fox N; McCarl CA; Tenner KS; Ballman K; Erskine CL; Necela BM; Northfelt D; Tan WW; Calfa C; Pegram M; Colon-Otero G; Perez EA; Clynes R; Knutson KL
    Breast Cancer Res; 2018 Jun; 20(1):52. PubMed ID: 29898752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Gianni L; Eiermann W; Semiglazov V; Lluch A; Tjulandin S; Zambetti M; Moliterni A; Vazquez F; Byakhov MJ; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Magazzù D; Heinzmann D; Steinseifer J; Valagussa P; Baselga J
    Lancet Oncol; 2014 May; 15(6):640-7. PubMed ID: 24657003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
    Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
    Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
    Cameron D; Piccart-Gebhart MJ; Gelber RD; Procter M; Goldhirsch A; de Azambuja E; Castro G; Untch M; Smith I; Gianni L; Baselga J; Al-Sakaff N; Lauer S; McFadden E; Leyland-Jones B; Bell R; Dowsett M; Jackisch C;
    Lancet; 2017 Mar; 389(10075):1195-1205. PubMed ID: 28215665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-World Outcomes of Adjuvant Chemotherapy for Node-Negative and Node-Positive HER2-Positive Breast Cancer.
    Veitch Z; Khan OF; Tilley D; Ribnikar D; Kostaras X; King K; Tang P; Lupichuk S
    J Natl Compr Canc Netw; 2019 Jan; 17(1):47-56. PubMed ID: 30659129
    [No Abstract]   [Full Text] [Related]  

  • 33. Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial.
    Láng I; Bell R; Feng FY; Lopez RI; Jassem J; Semiglazov V; Al-Sakaff N; Heinzmann D; Chang J
    Clin Oncol (R Coll Radiol); 2014 Feb; 26(2):81-9. PubMed ID: 24051172
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trastuzumab improves locoregional control in HER2-positive breast cancer patients following adjuvant radiotherapy.
    Cao L; Cai G; Xu F; Yang ZZ; Yu XL; Ma JL; Zhang Q; Wu J; Guo XM; Chen JY
    Medicine (Baltimore); 2016 Aug; 95(32):e4230. PubMed ID: 27512838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Effect of Adjuvant Trastuzumab on Locoregional Recurrence of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated with Mastectomy.
    Lanning RM; Morrow M; Riaz N; McArthur HL; Dang C; Moo TA; El-Tamer M; Krause K; Siu C; Hsu M; Zhang Z; Pei X; McCormick B; Powell SN; Ho A
    Ann Surg Oncol; 2015 Aug; 22(8):2517-25. PubMed ID: 25564167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial.
    Joensuu H; Fraser J; Wildiers H; Huovinen R; Auvinen P; Utriainen M; Nyandoto P; Villman KK; Halonen P; Granstam-Björneklett H; Lundgren L; Sailas L; Turpeenniemi-Hujanen T; Tanner M; Yachnin J; Ritchie D; Johansson O; Huttunen T; Neven P; Canney P; Harvey VJ; Kellokumpu-Lehtinen PL; Lindman H
    JAMA Oncol; 2018 Sep; 4(9):1199-1206. PubMed ID: 29852043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J; Perez EA; Pienkowski T; Bell R
    Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy of adjuvant trastuzumab in HER-2 positive breast cancer with axillary lymph node metastases according to the treatment duration.
    Sendur MA; Aksoy S; Ozdemir NY; Yazici O; Zengin N; Altundag K
    Curr Med Res Opin; 2014 Dec; 30(12):2535-42. PubMed ID: 25222762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG).
    İçli F; Altundağ K; Akbulut H; Paydaş S; Başaran G; Saip P; Doğu GG; Eralp Y; Uslu R; Sevinç A; Onur H; Mandel NM; Sezgin C; Altınbaş M; Güler N; Işıkdoğan A; Gökmen E; Uygun K; Üstüner Z; Yaren A; Demirkan B; Coşkun U; Ata A; Özkan M; Arican A
    Breast Cancer; 2015 Sep; 22(5):480-5. PubMed ID: 24338610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study.
    Goldhar HA; Yan AT; Ko DT; Earle CC; Tomlinson GA; Trudeau ME; Krahn MD; Krzyzanowska MK; Pal RS; Brezden-Masley C; Gavura S; Lien K; Chan KK
    J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26476433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 59.